Search research articles
Contact Us
Filters
Showing results (11-20 of 61) with videos related to
Page
of 7
Sort By:
Cancer
|
July 11, 2006
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma
Oliver Weigert, Tim Illidge, Wolfgang Hiddemann, et al.
The British Journal of Radiology
|
October 22, 2021
Lymphoma: advances in imaging and radiotherapy - introductory editorial
Tim Illidge, N George Mikhaeel, Lena Specht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2008
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
Andrey Ivanov, Sergei Krysov, Mark S Cragg, et al.
Expert Opinion on Biological Therapy
|
September 6, 2014
Update on obinutuzumab in the treatment of B-cell malignancies
Tim Illidge, Eleanor J Cheadle, Claire Donaghy, et al.
The Oncologist
|
December 7, 2014
Comment on: "clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study)"
Richard Hoppe, Tim Illidge, Lena Specht, et al.
Cancer Research
|
February 7, 2007
Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma
Yong Du, Jamie Honeychurch, Martin Glennie, et al.
Cancer Treatment Reviews
|
April 16, 2015
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders, Tim Illidge, Shankar Siva, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2015
Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group
Lena Specht, Bouthaina Dabaja, Tim Illidge, et al.
Cancer Treatment Reviews
|
July 21, 2015
Obinutuzumab in hematologic malignancies: lessons learned to date
Tim Illidge, Christian Klein, Laurie H Sehn, et al.
Haematologica
|
October 16, 2012
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
Adam Gibb, Craig Jones, Adrian Bloor, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 61) with videos related to
Sort By:
Page
of 7
Cancer
|
July 11, 2006
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma
Oliver Weigert, Tim Illidge, Wolfgang Hiddemann, et al.
The British Journal of Radiology
|
October 22, 2021
Lymphoma: advances in imaging and radiotherapy - introductory editorial
Tim Illidge, N George Mikhaeel, Lena Specht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 5, 2008
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
Andrey Ivanov, Sergei Krysov, Mark S Cragg, et al.
Expert Opinion on Biological Therapy
|
September 6, 2014
Update on obinutuzumab in the treatment of B-cell malignancies
Tim Illidge, Eleanor J Cheadle, Claire Donaghy, et al.
The Oncologist
|
December 7, 2014
Comment on: "clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study)"
Richard Hoppe, Tim Illidge, Lena Specht, et al.
Cancer Research
|
February 7, 2007
Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma
Yong Du, Jamie Honeychurch, Martin Glennie, et al.
Cancer Treatment Reviews
|
April 16, 2015
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders, Tim Illidge, Shankar Siva, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 13, 2015
Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group
Lena Specht, Bouthaina Dabaja, Tim Illidge, et al.
Cancer Treatment Reviews
|
July 21, 2015
Obinutuzumab in hematologic malignancies: lessons learned to date
Tim Illidge, Christian Klein, Laurie H Sehn, et al.
Haematologica
|
October 16, 2012
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
Adam Gibb, Craig Jones, Adrian Bloor, et al.
Page
of 7